Skip to content

Study · Not a test of the peptide alone · 2023

2 results

Can obesity exacerbate hyperinsulinaemia in the presence of the mutation of an insulin receptor gene?

Calcaterra V, Zuccotti G, Mari A, Iafusco F, Maione G, Iafusco D, Tinto N

Clinical obesity17 Sept 2023Cited by 3 (Europe PMC)

PMID37717597 (opens in a new tab)DOI10.1111/cob.12619 (opens in a new tab)PepBankPUB-37717597
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a 16-year-old girl with severe obesity and an INSR gene mutation, liraglutide given after limited benefit from metformin was followed by weight loss 3 months after initiation.

    In plain wordsIn one teenage girl with severe obesity and an insulin receptor gene change, weight fell after liraglutide, which was added after metformin helped little.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss 3 months after starting liraglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Metformin treatment provided limited benefits, but subsequent liraglutide therapy resulted in weight loss and decreased IR 3 months after initiation.
    1 context sentence
    Summary · context
    However, we present a unique case of severe obesity and Type A severe IR syndrome in a patient with a heterozygous mutation of the INSR gene.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a 16-year-old girl with severe obesity and an INSR gene mutation, liraglutide given after limited benefit from metformin was followed by decreased insulin resistance 3 months after initiation.

    In plain wordsIn one teenage girl with severe obesity and an insulin receptor gene change, insulin resistance fell after liraglutide, which was added after metformin helped little.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin resistance 3 months after starting liraglutide
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Metformin treatment provided limited benefits, but subsequent liraglutide therapy resulted in weight loss and decreased IR 3 months after initiation.
    1 context sentence
    Summary · context
    However, we present a unique case of severe obesity and Type A severe IR syndrome in a patient with a heterozygous mutation of the INSR gene.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.